The role of TIGIT as a target for immuno-oncology therapies has been called into question again after it was revealed that Novartis handed back rights to a drug partnered with China’s BeiGene.

Bristol-Myers Squibb has handed back rights to a TIGIT drug partnered with Agenus, ending an alliance that could have been worth up to $1.56 billion to the biotech. Agenus revealed BMS' decision ...